证券之星消息，1月16日医疗器械板块较上一交易日下跌1.58%，康众医疗领跌。当日上证指数报收于 4101.91，下跌0.26%。深证成指报收于14281.08，下跌0.18%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 301235 | 华康洁净 | 48.22 | 20.01% | | 15.64万 | 7.07亿 | | 688301 | 奕瑞科技 | 116.55 | 4.60% | | 3.19万 | 3.69亿 | | 688351 | 微电生理 | 27.28 | 3.61% | | 6.89万 | 1.85 亿 | | 301515 | 港通医疗 | 25.93 | 2.98% | | 6.54万 | 1.67亿 | | 603301 | 振德医疗 | 70.50 | 2.49% | | 2.53万 | 1.76亿 | | 688253 | 英诺特 | 35.43 | 1.93% | | 3.49万 | 1.22亿 | | 300 ...

截至2026年1月9日收盘，振德医疗（603301）报收于69.6元，较上周的70.5元下跌1.28%。本周，振德 医疗1月5日盘中最高价报72.97元。1月9日盘中最低价报67.83元。振德医疗当前最新总市值185.02亿 元，在医疗器械板块市值排名16/127，在两市A股市值排名1123/5182。 本周关注点 公司公告汇总 北京国枫(杭州)律师事务所出具法律意见书，确认振德医疗2026年第一次临时股东大会的召集、召开程 序，召集人和出席会议人员资格，会议表决程序及表决结果均符合相关法律法规及公司章程的规定，合 法有效。本次会议审议通过了关于变更公司住所及修改公司章程并办理工商变更登记的提案。 振德医疗第一期员工持股计划延长后的存续期已于2026年1月2日届满，所持股份已全部处置完毕，计划 终止。该计划于2021年7月1日完成非交易过户，共持有2,100,000股，占当时总股本0.92%。第一、第二 个解锁期合计解锁1,484,333股，第三个解锁期未达标。2025年11月27日，未解锁的615,667股已完成回 购注销。公司后续将按规定完成资产清算和分配。 振德医疗用品股份有限公司于2025年12月15 ...

住所：浙江省绍兴市越城区皋埠街道香积路55号 法定代表人：鲁建国 注册资本：贰亿陆仟伍佰捌拾叁万伍仟伍佰叁拾伍元 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）于2025年12月15日和2026年1月5日分别召开第四届董事 会第五次会议和2026年第一次临时股东会，审议通过了《关于变更公司住所及修改〈公司章程〉并办理 工商变更登记的议案》，具体内容详见公司在上海证券交易所网站（www.sse.com.cn）、《中国证券 报》、《上海证券报》、《证券日报》、《证券时报》上披露的《振德医疗关于变更公司住所及修改 〈公司章程〉并办理工商变更登记的公告》（公告编号：2025-045）和《振德医疗2026年第一次临时股 东会决议公告》（公告编号：2026-002）。 公司于近日完成了上述工商变更登记和相关备案手续，公司住所由"浙江省绍兴市越城区皋埠街道皋北 工业区"变更为"浙江省绍兴市越城区皋埠街道香积路55号"，并取得了浙江省市场监督管理局换发的 《营业执照》，公司相关登记信息如下： 统一 ...

证券代码：603301 证券简称：振德医疗 公告编号：2026-003 振德医疗用品股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）于 2025 年 12 月 15 日和 2026 年 1 月 5 日分别召开第四届董事会第五次会议和 2026 年第一次临时股东会，审议通过了《关于变更公司住所及修改<公司 章程>并办理工商变更登记的议案》，具体内容详见公司在上海证券交 易所网站（www.sse.com.cn）、《中国证券报》、《上海证券报》、《证券 日报》、《证券时报》上披露的《振德医疗关于变更公司住所及修改< 公司章程>并办理工商变更登记的公告》（公告编号：2025-045）和《振 德医疗 2026 年第一次临时股东会决议公告》（公告编号：2026-002）。 公司于近日完成了上述工商变更登记和相关备案手续，公司住所 由"浙江省绍兴市越城区皋埠街道皋北工业区"变更为"浙江省绍兴 市越城区皋埠街道香积路 55 号"，并取得了浙江省市场监督管理局 ...

1月6日主力资金净流入46.37万元，占总成交额0.18%；游资资金净流入1984.93万元，占总成交额 7.61%；散户资金净流出2031.31万元，占总成交额7.78%。 公司公告汇总振德医疗2026年第一次临时股东会决议公告 振德医疗于2026年1月5日召开2026年第一次临时股东会，审议通过《关于变更公司住所及修改并办理工 商变更登记的提案》。会议由董事长鲁建国主持，采用现场与网络投票结合方式召开，出席股东所持表 决权占公司总股本的55.8030%。议案为特别决议事项，已获出席会议股东所持表决权的三分之二以上 通过。北京国枫（杭州）律师事务所对本次会议进行了见证并出具法律意见书，认为会议召集、召开程 序及表决结果合法有效。 北京国枫（杭州）律师事务所关于振德医疗用品股份有限公司2026年第一次临时股东会的法律意见书 北京国枫(杭州)律师事务所出具法律意见书，认为振德医疗用品股份有限公司2026年第一次临时股东大 会的召集、召开程序，召集人和出席会议人员资格，会议表决程序及表决结果均符合相关法律法规及公 司章程的规定，合法有效。本次会议审议通过了关于变更公司住所及修改公司章程并办理工商变更登记 的提案。 ...

证券代码：603301 证券简称：振德医疗 公告编号：2026-002 振德医疗用品股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2026年1月5日 (二)股东会召开的地点：浙江省绍兴市越城区皋埠街道香积路55号振德医 疗用品股份有限公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由公司董事会召集，以现场投票和网络投票相结合的方式召开，由董事长鲁建国先生主持会 议。本次会议的召集、召开及表决方式符合《公司法》及《公司章程》的规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事9人，列席8人，其中董事沈振东因公未能列席本次会议，董事李婕，独立董事倪崖、 朱茶芬以视频会议方式列席本次会议。 2、董事会秘书季宝海列席本次股东会；公司部分高管列席了会议。 二、议案 ...

截至2026年1月5日收盘，振德医疗(603301)报收于71.56元，上涨1.5%，换手率1.46%，成交量3.87万 手，成交额2.77亿元。 当日关注点 交易信息汇总资金流向 1月5日主力资金净流出1704.33万元，占总成交额6.16%；游资资金净流入1495.06万元，占总成交额 5.4%；散户资金净流入209.27万元，占总成交额0.76%。 公司公告汇总振德医疗2026年第一次临时股东会决议公告 振德医疗于2026年1月5日召开2026年第一次临时股东会，审议通过《关于变更公司住所及修改并办理工 商变更登记的提案》。会议由董事长鲁建国主持，采用现场与网络投票结合方式召开，出席股东所持表 决权占公司总股本的55.8030%。议案为特别决议事项，已获出席会议股东所持表决权的三分之二以上 通过。北京国枫（杭州）律师事务所对本次会议进行了见证并出具法律意见书，认为会议召集、召开程 序及表决结果合法有效。 北京国枫（杭州）律师事务所关于振德医疗用品股份有限公司2026年第一次临时股东会的法律意见书 北京国枫(杭州)律师事务所出具法律意见书，认为振德医疗用品股份有限公司2026年第一次临时股东大 会的召集、 ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

证券代码：603301 证券简称：振德医疗 公告编号：2026-001 振德医疗用品股份有限公司 关于第一期员工持股计划存续期 届满暨终止的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）第一期员工持 股计划（以下简称"本员工持股计划"）延长后的存续期已于 2026 年 1 月 2 日届满。根据中国证监会《关于上市公司实施员工持股计划试 点的指导意见》《上海证券交易所上市公司自律监管指引第 1 号—规 范运作》等相关规定，公司现将相关情况公告如下： 一、本员工持股计划的基本情况 公司分别于 2021 年 5 月 24 日、2021 年 6 月 15 日召开第二届董 事会第十七次会议和 2021 年第二次临时股东大会，审议通过了《关 于<公司第一期员工持股计划（草案）>及其摘要的议案》等相关议案， 同意实施公司第一期员工持股计划，具体内容详见公司于 2021 年 5 月 25 日、2021 年 6 月 16 日在上海证券交易所网站（www.sse.com.cn） 披露的公告。 公 ...

法律意见书 国枫律股字[2026] G0001 号 杭州市上城区新业路8号华联时代大 电话:0571-88362156 传真: 0571-88362156 邮编· 310016 北京国枫(杭州)律师事务所 关于振德医疗用品股份有限公司 2026 年第一次临时股东会的 致:振德医疗用品股份有限公司(贵公司) 北京国枫(杭州)律师事务所(以下简称"本所")接受贵公司的委托,指派律师 出席并见证贵公司 2026年第一次临时股东会(以下简称"本次会议")。 本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以下简称 "《股东会规则》")、《律师事务所从事证券法律业务管理办法》(以下简称"《证券法律 业务管理办法》")、《律师事务所证券法律业务执业规则(试行)》(以下简称"《证券法 律业务执业规则》")等相关法律、行政法规、规章、规范性文件及《振德医疗用品股份 有限公司章程》(以下简称"《公司章程》"）的规定,就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜,出具本法律意见书。 对本法律意 ...